Johns Hopkins School of Medicine

DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO

Retrieved on: 
Tuesday, September 27, 2022

The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.

Key Points: 
  • The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.
  • Mr. Grmusa, Dr. Quva and Dr. Francisco-Anderson join experienced industry leader John McCabe who serves as Chief Financial Officer and Chief Operating Officer.
  • I am thrilled to join DEM Bio and to work alongside this world-class team of leaders in the emerging and highly promising field of innate immune system checkpoint inhibitors, said Mr. Grmusa.
  • Mr. Grmusa brings 20 years of industry experience in business development, pharmaceutical portfolio management, R&D finance and financial planning and analysis.

ONWARD Announces Appointment of Vivian Riefberg to Board of Directors

Retrieved on: 
Monday, September 26, 2022

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors.
  • Her appointment to the Board will be presented for shareholder approval at the next Annual General Meeting.
  • View the full release here: https://www.businesswire.com/news/home/20220926005494/en/
    Vivian Riefberg joins the ONWARD Medical Board of Directors (Photo: Business Wire)
    Vivian Riefberg is a distinguished expert in health care, government, and strategy.
  • ONWARD has the opportunity to build a very special enterprise that is both successful and impactful, said Vivian Riefberg.

REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting

Retrieved on: 
Monday, September 26, 2022

ROCKVILLE, Md., Sept. 26, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions.

Key Points: 
  • ET to discuss new, interim data from the ongoing Phase II AAVIATE trial
    ROCKVILLE, Md., Sept. 26, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL.
  • The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions.
  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
  • REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Featherstone Foundation Awards $90,000 in College Scholarships to 30 Exceptional Baltimore Area Students

Retrieved on: 
Friday, September 23, 2022

BALTIMORE, Sept. 23, 2022 /PRNewswire/ -- The William & Lanaea C. Featherstone Foundation , an award-winning nonprofit, touts its Featherstone College Scholarship Award recipients.

Key Points: 
  • BALTIMORE, Sept. 23, 2022 /PRNewswire/ -- The William & Lanaea C. Featherstone Foundation , an award-winning nonprofit, touts its Featherstone College Scholarship Award recipients.
  • This year, 30 exceptional Featherstone Scholars will receive $3,000 merit-based scholarships during a special awards ceremony on Friday Sept. 23 at noon.
  • "She reinforces our values that higher education is a gateway to economic opportunities for all," said Juliana Lopez, executive director, William & Lanaea C. Featherstone Foundation.
  • Since 2017, the Featherstone Foundation has provided more than $236,000 through 98 scholarships to students from 20 countries who now attend 12 institutions.

Cool Comedy • Hot Cuisine: A Tribute to Bob Saget Raises More Than $1.2M for Scleroderma Research Foundation

Retrieved on: 
Friday, September 23, 2022

Some of the world's most talented performers generously donated their time to take to the stage to raise funds for the Scleroderma Research Foundation and to find a cure.

Key Points: 
  • Some of the world's most talented performers generously donated their time to take to the stage to raise funds for the Scleroderma Research Foundation and to find a cure.
  • Cool Comedy Hot Cuisine featured performances byHowie Mandel and Kevin Nealon, with Joel McHale leading the live auction.
  • As a longtime supporter and board member of Scleroderma Research Foundationthe country's first and leading nonprofit investor in medical research into sclerodermaBob Saget spearheaded Cool Comedy Hot Cuisine for 30 years.
  • The Scleroderma Research Foundation is focused on bringing the best minds in science together to find a cure for scleroderma.

New Book on Global Populism Examines Psychology of Blame-Shifting and the Corruption of Democracy

Retrieved on: 
Monday, September 19, 2022

As a follow up to her 2020 book Aftermath: Healing from the Trump Presidency, here Messina examines populism in the U.S., Hungary, Poland, Austria, Australia, New Zealand, Western Europe, Latin America, the Philippines, Turkey, and India.

Key Points: 
  • As a follow up to her 2020 book Aftermath: Healing from the Trump Presidency, here Messina examines populism in the U.S., Hungary, Poland, Austria, Australia, New Zealand, Western Europe, Latin America, the Philippines, Turkey, and India.
  • The book is endorsed by leading psychoanalysts, including David Scharff and Richard Waugaman.
  • Adds Waugaman: Messina "cogently applies psychoanalytic thinking to a host of serious dangers that threaten democracy.
  • For more information go to: Home (karyne-messina.com)
    Resurgence of Global Populism: A Psychoanalytic Study of Projective Identification, Blame- Shifting and the Corruption of Democracy by Karyne Messina

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

Retrieved on: 
Thursday, September 15, 2022

Prior to Agilent, Dr. Knobil served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences.

Key Points: 
  • Prior to Agilent, Dr. Knobil served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences.
  • Dr. Knobil currently serves on the Board of Marker Therapeutics and previously served on the Board of Arena Pharmaceuticals, prior to its acquisition by Pfizer.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter , LinkedIn , Facebook and YouTube .

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Retrieved on: 
Saturday, September 10, 2022

MADISON, Wis., Sept. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the performance of four distinct biomarker classes found in the blood and known to signal the presence of cancer regardless of its location in the body.

Key Points: 
  • "Robust studies like this one are important in understanding the potential effectiveness of a multi-biomarker approach to MCED.
  • Exact Sciences will then begin recruiting patients for the FDA registrational Study Of All comeRs (SOAR) trial in MCED during 2023.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • For more information, please visit the company's website at exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

Retrieved on: 
Saturday, September 10, 2022

MADISON, Wis., Sept. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the performance of four distinct biomarker classes found in the blood and known to signal the presence of cancer regardless of its location in the body.

Key Points: 
  • "Robust studies like this one are important in understanding the potential effectiveness of a multi-biomarker approach to MCED.
  • Exact Sciences will then begin recruiting patients for the FDA registrational Study Of All comeRs (SOAR) trial in MCED during 2023.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier.
  • For more information, please visit the company's website at exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Cannabis Science Conference East Announces Keynote Speakers for Conference at Baltimore Convention Center September 14-16, 2022

Retrieved on: 
Thursday, September 8, 2022

Baltimore, MD, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Science Conference (CSC), the world's largest and fastest-growing scientific and medical cannabis conference specializing in medical cannabis, analytical science, cultivation, hemp/CBD and psychedelic sciences, announced today the upcoming shows list of keynote speakers and partners coming to the Baltimore Convention Center from September 14-16, 2022 for the three-day immersive event.

Key Points: 
  • Baltimore, MD, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cannabis Science Conference (CSC), the world's largest and fastest-growing scientific and medical cannabis conference specializing in medical cannabis, analytical science, cultivation, hemp/CBD and psychedelic sciences, announced today the upcoming shows list of keynote speakers and partners coming to the Baltimore Convention Center from September 14-16, 2022 for the three-day immersive event.
  • Cannabis Science Conference Easts 2022 conference keynote speakers include Plenary speaker Dr. David Dedi Meiri of Technion in Israel, who heads up the institutes cancer and cannabinoid research.
  • Registration information for both Cannabis Science Conference East and the Canna Boot Camp can be found via their website by clicking here .
  • Cannabis Science Conference East in Baltimore will approach the cannabis and psychedelic industries from an educational perspective, featuring five expert-led tracks including: Analytical/Science, Medical Cannabis, Cultivation, Hemp/CBD, and new for 2022, the Psychedelic track.